AR029666A1 - Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina - Google Patents
Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopaminaInfo
- Publication number
- AR029666A1 AR029666A1 ARP010102464A ARP010102464A AR029666A1 AR 029666 A1 AR029666 A1 AR 029666A1 AR P010102464 A ARP010102464 A AR P010102464A AR P010102464 A ARP010102464 A AR P010102464A AR 029666 A1 AR029666 A1 AR 029666A1
- Authority
- AR
- Argentina
- Prior art keywords
- dementia
- dopamine
- fluorophenyl
- ethyl
- manufacture
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Abstract
Uso de (+)- alfa (2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinilmetanol, o una sal farmacéuticamente aceptable del mismo; o una prodroga, su estereoisomero o sal farmacéuticamente aceptable del mismo, en donde la prodroga es: de formula (2) en la cual R es alquilo de C1-20 para manufactura de un medicamento para el tratamiento de los síntomas de comportamiento, psicologicos o motores de la demencia por administracion a un paciente que tiene demencia y psicosis inducida por dopamina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20694300P | 2000-05-25 | 2000-05-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR029666A1 true AR029666A1 (es) | 2003-07-10 |
Family
ID=22768607
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010102464A AR029666A1 (es) | 2000-05-25 | 2001-05-23 | Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina |
Country Status (20)
Country | Link |
---|---|
US (3) | US20020099076A1 (es) |
EP (1) | EP1289527B1 (es) |
JP (1) | JP2003535058A (es) |
KR (1) | KR100784655B1 (es) |
CN (1) | CN1436078A (es) |
AR (1) | AR029666A1 (es) |
AT (1) | ATE390134T1 (es) |
AU (2) | AU2001264842B2 (es) |
BR (1) | BR0111102A (es) |
CA (1) | CA2410554C (es) |
DE (1) | DE60133385T2 (es) |
DK (1) | DK1289527T3 (es) |
ES (1) | ES2300333T3 (es) |
IL (1) | IL152908A0 (es) |
MX (1) | MXPA02011511A (es) |
NO (1) | NO20025630L (es) |
NZ (1) | NZ522659A (es) |
PT (1) | PT1289527E (es) |
TW (1) | TWI299001B (es) |
WO (1) | WO2001089498A2 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004009586A1 (en) | 2002-07-19 | 2004-01-29 | Biovitrum Ab | Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders |
ES2643615T3 (es) * | 2004-09-30 | 2017-11-23 | F. Hoffmann-La Roche Ag | Composiciones y métodos para el tratamiento de trastornos cognitivos |
US7713954B2 (en) | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
DE102006040278A1 (de) * | 2006-08-21 | 2008-03-20 | Technische Universität Dresden | Arzneimittel zur Behandlung des Charles-Bonnet-Syndroms |
PT3325444T (pt) | 2015-07-20 | 2021-09-22 | Acadia Pharm Inc | Métodos para preparar n-(4-fluorobenzil)-n-(1-metilpiperidina-4-il)-n'-(4-(2-metilpropiloxi)fenilmetil)carbamida e o seu sal de tartarato e forma polimórfica c |
US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
WO2017172757A1 (en) * | 2016-03-29 | 2017-10-05 | Acadia Pharmaceuticals Inc. | 5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques |
EP3558311A1 (en) | 2016-12-20 | 2019-10-30 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis |
EP3615028A1 (en) | 2017-04-28 | 2020-03-04 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
US20210077479A1 (en) | 2017-08-30 | 2021-03-18 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5021428A (en) * | 1985-07-02 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Novel chemical compounds for the prophylactic treatment of migraine |
US4912117A (en) * | 1985-07-02 | 1990-03-27 | Merrell Dow Pharmaceuticals Inc. | Novel chemical compounds |
US4783471A (en) * | 1985-07-02 | 1988-11-08 | Merrell Dow Pharmaceuticals Inc. | N-aralkyl piperidine methanol derivatives and the uses thereof |
US5169096A (en) * | 1985-07-02 | 1992-12-08 | Merrell Dow Pharmaceuticals Inc. | N-aralkyl-piperidine-methanol derivatives |
US4877798A (en) * | 1987-11-23 | 1989-10-31 | Merrell Dow Pharmaceuticals Inc. | Treatment of fibromyalgia |
EP0325063B1 (en) * | 1988-01-21 | 1994-03-09 | Merrell Dow Pharmaceuticals Inc. | Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia |
US5106855A (en) * | 1989-12-20 | 1992-04-21 | Merrell Dow Pharmaceuticals Inc. | Method for the treatment of glaucoma |
AU652759B2 (en) * | 1990-06-01 | 1994-09-08 | Aventisub Ii Inc. | (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)- 4-piperidinemethanol |
US6004980A (en) * | 1990-06-01 | 1999-12-21 | Merrell Pharmaceuticals, Inc. | (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
US5618824A (en) * | 1994-03-09 | 1997-04-08 | Merrell Pharmaceuticals Inc. | Treatment of obsessive-compulsive disorders with 5-HT2 antagonists |
FR2738819B1 (fr) * | 1995-09-14 | 1997-12-05 | Sanofi Sa | Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant |
EP0796619A1 (en) * | 1996-03-21 | 1997-09-24 | Merrell Pharmaceuticals Inc. | Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders |
US6028083A (en) * | 1997-07-25 | 2000-02-22 | Hoechst Marion Roussel, Inc. | Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol |
AU1118099A (en) * | 1997-10-23 | 1999-05-10 | Research Foundation Of The State University Of New York, The | Methods of screening potential atypical antipsychotic drugs |
HUP0202145A3 (en) * | 1998-08-28 | 2003-02-28 | Aventis Pharmaceuticals Inc Br | The use of r(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of sleep disorders |
IL142479A0 (en) * | 1998-10-14 | 2002-03-10 | Aventis Pharma Inc | Esters of (+)-alpha-(2,3-dimethoxyphenyl) -1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907 |
US6455526B1 (en) * | 1998-12-16 | 2002-09-24 | Aventis Pharmaceuticals, Inc. | Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same |
-
2001
- 2001-05-18 US US09/861,980 patent/US20020099076A1/en not_active Abandoned
- 2001-05-23 ES ES01939312T patent/ES2300333T3/es not_active Expired - Lifetime
- 2001-05-23 CN CN01810983A patent/CN1436078A/zh active Pending
- 2001-05-23 WO PCT/US2001/016653 patent/WO2001089498A2/en active IP Right Grant
- 2001-05-23 PT PT01939312T patent/PT1289527E/pt unknown
- 2001-05-23 IL IL15290801A patent/IL152908A0/xx unknown
- 2001-05-23 MX MXPA02011511A patent/MXPA02011511A/es active IP Right Grant
- 2001-05-23 TW TW090112318A patent/TWI299001B/zh not_active IP Right Cessation
- 2001-05-23 JP JP2001585743A patent/JP2003535058A/ja active Pending
- 2001-05-23 CA CA002410554A patent/CA2410554C/en not_active Expired - Fee Related
- 2001-05-23 EP EP01939312A patent/EP1289527B1/en not_active Expired - Lifetime
- 2001-05-23 DK DK01939312T patent/DK1289527T3/da active
- 2001-05-23 KR KR1020027015968A patent/KR100784655B1/ko not_active IP Right Cessation
- 2001-05-23 NZ NZ522659A patent/NZ522659A/en unknown
- 2001-05-23 AR ARP010102464A patent/AR029666A1/es unknown
- 2001-05-23 AU AU2001264842A patent/AU2001264842B2/en not_active Ceased
- 2001-05-23 BR BR0111102-7A patent/BR0111102A/pt not_active Application Discontinuation
- 2001-05-23 DE DE60133385T patent/DE60133385T2/de not_active Expired - Fee Related
- 2001-05-23 AT AT01939312T patent/ATE390134T1/de not_active IP Right Cessation
- 2001-05-23 AU AU6484201A patent/AU6484201A/xx active Pending
-
2002
- 2002-08-13 US US10/217,843 patent/US20030036553A1/en not_active Abandoned
- 2002-11-22 NO NO20025630A patent/NO20025630L/no not_active Application Discontinuation
-
2004
- 2004-05-03 US US10/838,035 patent/US7132433B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
NZ522659A (en) | 2004-06-25 |
NO20025630L (no) | 2003-01-24 |
DE60133385D1 (de) | 2008-05-08 |
ES2300333T3 (es) | 2008-06-16 |
BR0111102A (pt) | 2003-03-11 |
EP1289527B1 (en) | 2008-03-26 |
DK1289527T3 (da) | 2008-07-14 |
KR20030034078A (ko) | 2003-05-01 |
PL359176A1 (en) | 2004-08-23 |
PT1289527E (pt) | 2008-05-13 |
MXPA02011511A (es) | 2003-04-25 |
NO20025630D0 (no) | 2002-11-22 |
ATE390134T1 (de) | 2008-04-15 |
CA2410554A1 (en) | 2001-11-29 |
KR100784655B1 (ko) | 2007-12-12 |
AU6484201A (en) | 2001-12-03 |
JP2003535058A (ja) | 2003-11-25 |
IL152908A0 (en) | 2003-06-24 |
US20030036553A1 (en) | 2003-02-20 |
US20040204457A1 (en) | 2004-10-14 |
US7132433B2 (en) | 2006-11-07 |
AU2001264842B2 (en) | 2005-01-27 |
CN1436078A (zh) | 2003-08-13 |
DE60133385T2 (de) | 2009-04-23 |
TWI299001B (en) | 2008-07-21 |
WO2001089498A3 (en) | 2002-05-10 |
CA2410554C (en) | 2009-02-03 |
EP1289527A2 (en) | 2003-03-12 |
US20020099076A1 (en) | 2002-07-25 |
WO2001089498A2 (en) | 2001-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
UY29085A1 (es) | Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes | |
ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
AR037517A1 (es) | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria | |
ECSP066313A (es) | Derivados de la piridazina y su uso como agentes terapéuticos | |
AR035927A1 (es) | Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr | |
CO5640076A2 (es) | Composicion farmaceutica que comprende un inhibidor de ibat para el tratamiento o profilaxis del estreñimiento | |
ECSP066312A (es) | Derivados piridilo y su uso como agentes terapéuticos | |
PA8591701A1 (es) | Derivados de pirrolopirimidina | |
UY27533A1 (es) | Composiciones farmacéuticas que contienen oxibutinina | |
PE20040134A1 (es) | Forma de dosificacion de una vez al dia de pramipexol | |
PE20061314A1 (es) | Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo | |
ECSP088973A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
AR073265A1 (es) | Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio | |
AR060019A1 (es) | Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo | |
AR020803A1 (es) | Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento | |
AR029666A1 (es) | Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina | |
AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
ES2570401T3 (es) | Métodos de tratamiento usando dosis únicas de oritavancina | |
AR021912A1 (es) | Uso de apomorfina para el tratamiento de la disfuncion erectil organica en varones | |
AR043259A1 (es) | Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello | |
CO5700723A2 (es) | Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca | |
AR046036A1 (es) | Composiciones de risedronato y metodos para su uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |